High dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis

BACKGROUND: Ursodeoxycholic acid (UDCA) in a dose of 28–30 mg/kg/day increases the likelihood of clinical deterioration of primary sclerosing cholangitis (PSC) patients. AIM: Our aim was to compare the risk of adverse clinical endpoints in patients with varying disease status. METHODS: We reviewed r...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Imam, Mohamad H., Sinakos, Emmanouil, Gossard, Andrea A., Kowdley, Kris V., Luketic, Velimir A. C., Harrison, M. Edwyn, McCashland, Timothy, Befeler, Alex S., Harnois, Denise, Jorgensen, Roberta, Petz, Jan, Keach, Jill, DeCook, Alisha C., Enders, Felicity, Lindor, Keith D.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2011
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3752281/
https://ncbi.nlm.nih.gov/pubmed/21957881
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2036.2011.04863.x
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi